Esophageal Cancer Clinical Trials in New York, New York

17 studies are recruiting for esophageal cancer in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

    This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma [cutaneous/acral], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric can…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Hospital, New York, New York
    Locations
    90 in total
    Run by
    Daiichi Sankyo

    See if you can join NCT06172478 on ClinicalTrials.gov

  2. Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.

    This is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of [¹⁸F]FAPI-74 PET/CT in the detection of metastatic disease in individuals with pathologically confirmed gastric, gastroesophageal junction or esophageal cancer. Following screening, using a standar…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Icahn School of Medicine at Mount Sinai, New York, New York
    Locations
    16 in total
    Run by
    SOFIE

    See if you can join NCT07217704 on ClinicalTrials.gov

  3. A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma

    The purpose of this study is to find out whether adding the drug 2141-V11 to standard treatment (anti-PD-1 immunotherapy with or without 5-FU) is a safe treatment approach for participants with advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York, New York
    Locations
    7 in total
    Run by
    Memorial Sloan Kettering Cancer Center

    See if you can join NCT07818018 on ClinicalTrials.gov

  4. Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

    The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York, New York
    Locations
    26 in total
    Run by
    SystImmune Inc.

    See if you can join NCT06293898 on ClinicalTrials.gov

  5. Retrospective Review of Esophageal Cancer at MSKCC

    Residual tumor at the proximal or distal margin after esophagectomy is a known prognostic factor for poor survival outcomes in patients with esophageal cancer; however, the significance of the circumferential resection margin (CRM) remains controversial. In this study, the investigators sought to e…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York
    Run by
    Memorial Sloan Kettering Cancer Center

    See if you can join NCT05706558 on ClinicalTrials.gov

  6. Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

    The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor receptor 2 (HER2)-negative, gastric, gastroesophageal junction (GE…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Research Site, New York, New York
    Locations
    311 in total
    Run by
    AstraZeneca

    See if you can join NCT07431281 on ClinicalTrials.gov

  7. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

    The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York, New York
    Locations
    39 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT06465069 on ClinicalTrials.gov

  8. Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

    This is a phase 1/2 multicenter, open-label umbrella platform study that will evaluate the safety and efficacy of sacituzumab tirumotecan (MK-2870) plus paclitaxel versus ramucirumab plus paclitaxel, and HER3-DXD plus ramucirumab versus ramucirumab plus paclitaxel for the treatment of participants …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Columbia University Irving Medical Center-CUIMC Herbert Irving Comprehensive Cancer Center Clinical ( Site 8907), New York, New York
    Locations
    46 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT06445972 on ClinicalTrials.gov

  9. Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

    This is a phase 1/2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of investigational agents with pembrolizumab and fluoropyrimidine chemotherapy for the first-line (1L) treatment of participants with locally advanced unresectable or metastatic human…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Columbia University Irving Medical Center-CUIMC Herbert Irving Comprehensive Cancer Center Clinical ( Site 6907), New York, New York
    Locations
    50 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT06469944 on ClinicalTrials.gov

  10. A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

    This is a study to evaluate the safety and preliminary anti-tumor activity of STRO-004 in adults with metastatic cancer. This study includes 3 parts: * Part 1A is a dose escalation study of STRO-004 monotherapy in selected tumor types known to commonly express Tissue Factor (TF). * Part 1B is a coh…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York
    Locations
    9 in total
    Run by
    Sutro Biopharma, Inc.

    See if you can join NCT07227168 on ClinicalTrials.gov

  11. A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

    This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been completed and the RP2D will be further evaluated in an expansio…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Mt. Sinai, New York, New York
    Locations
    54 in total
    Run by
    Merus B.V.

    See if you can join NCT03526835 on ClinicalTrials.gov

  12. A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

    The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center, New York, New York
    Locations
    28 in total
    Run by
    Jazz Pharmaceuticals

    See if you can join NCT06695845 on ClinicalTrials.gov

  13. A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer

    The purpose of this study to find out whether adding trastuzumab and pembrolizumab to standard chemotherapy is an effective treatment for resectable HER2+ esophagogastric cancer.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York
    Locations
    10 in total
    Run by
    Memorial Sloan Kettering Cancer Center

    See if you can join NCT06123338 on ClinicalTrials.gov

  14. Registry for Esophageal and Gastroesophageal Junction Cancer

    The purpose of this registry study is to create a database-a collection of information-for better understanding standard treatments for esophageal and Gastroesophageal Junction Cancer/GEJ cancer. Researchers will use the information from this database to learn more about the effectiveness of differ…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York
    Run by
    Memorial Sloan Kettering Cancer Center

    See if you can join NCT06558786 on ClinicalTrials.gov

  15. Brodalumab in the Treatment of Immune-Related Adverse Events

    The purpose of this study is to test the safety and effectiveness of using brodalumab in patients who develop side effects from cancer immune therapy. Immune-related side effects are due to activation of the immune system in patients who previously received immunotherapy and the goal of this study …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Columbia University Irving Medical Center, New York, New York
    Run by
    Brian Henick, MD

    See if you can join NCT06673329 on ClinicalTrials.gov

  16. Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

    The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center Head Neck Services, New York, New York
    Locations
    39 in total
    Run by
    SystImmune Inc.

    See if you can join NCT05983432 on ClinicalTrials.gov

  17. VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

    This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curat…

    Stage
    Phase 1
    Ages
    18 to 80
    Site
    Weill Cornell Medicine, Cornell University (site 126), New York, New York
    Locations
    15 in total
    Run by
    VM Oncology, LLC

    See if you can join NCT03556228 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.